Clinical trials: Neoplasms, Germ Cell and Embryonal
Cancer, Young Adult
Symptom Management for YA Cancer Survivors
Symptom interference is common for survivors of young adult cancer (aged 18-39 at diagnosis) and impacts their abilities to achieve normative life goals (e.g., education, careers, independence, romantic/social relationships) as…
- Conditions
- Cancer, Young Adult, Pain, Psychological Distress
- Trial name
- NCT04035447
- Testing
- Behavioral Symptom Management for Young Adult Cancer Survivors
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Duke University
Melanoma
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
The purpose of this clinical research study is to examine the safety and effectiveness (how well the drug works) of two different treatments for patients with melanoma.
- Trial name
- NCT00324155
- Testing
- Ipilimumab, Dacarbazine
- Where
- 127 sites in United States, Argentina and 23 more
- Volunteers
- 681 people
- Sponsor
- Bristol-Myers Squibb
Neuroendocrine Tumor, Anaplastic Thyroid Cancer
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
CABATEN is a multicohort phase II study of cabozantinib plus atezolizumab in advanced and progressive tumors from endocrine system.
- Conditions
- Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma
- Trial name
- CABATEN (NCT04400474)
- Testing
- Cabozantinib 40 mg
- Where
- 15 sites in Spain
- Volunteers
- 93 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Neuroblastoma
Study of MLN8237 in Combination With Irinotecan and Temozolomide
The goal of the first part of this clinical trial (Phase I portion) is to study the side effects, drug breakdown (pharmacokinetics), and dosing of the drug MLN8237 when added to standard chemotherapy drugs, irinotecan and…
- Trial name
- NCT01601535
- Testing
- MLN8237, Irinotecan, Temozolomide
- Where
- 13 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Melanoma
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
The goal of this clinical research study is to learn if the combination of 2 drugs dabrafenib and trametinib can help to control melanoma that has or has not spread to the brain.
- Trial name
- NCT01619774
- Testing
- GSK2118436, GSK1120212
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
The primary objective of this extension study was to further assess the safety and tolerability of talimogene laherparepvec. Secondary objectives were to assess objective tumor response rate and survival.
- Trial name
- NCT02574260
- Testing
- Talimogene Laherparepvec
- Volunteers
- 3 people
- Sponsor
- BioVex Limited
Melanoma
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)
This is an extended use study for patients who have received 10 doses of CAVATAK™ in the VLA 007 trial. There may be patients who have benefitted from the study drug and who might benefit from further treatment.
- Trial name
- CALMext (NCT01636882)
- Testing
- CVA21
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Viralytics
Advanced Malignancies
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v.
- Trial name
- NCT02608268
- Testing
- MBG453, PDR001, Decitabine
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma
Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)
The purpose of this program is to evaluate the safety, tolerability, and efficacy of the new concomitant and sequential temozolomide regimen in newly diagnosed Glioblastoma patients in a routine care setting.
- Trial name
- NCT00725010
- Testing
- Temozolomide, Radiotherapy
- Volunteers
- 64 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
The purpose of this study is to find out what effects an experimental drug, called interleukin 21 or rIL-21, will have on malignant melanoma and whether these effects look promising compared to dacarbazine.
- Trial name
- NCT01152788
- Testing
- rIL-21, Dacarbazine
- Where
- 19 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- NCIC Clinical Trials Group
Brain and Central Nervous System Tumors
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00486603
- Testing
- hydroxychloroquine, temozolomide, pharmacological study
- Where
- 9 sites in United States
- Volunteers
- 92 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Malignant Melanoma
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
This open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600 mutation-positive metastatic melanoma.
- Trial name
- NCT01271803
- Testing
- Cobimetinib, vemurafenib
- Where
- 10 sites in United States, Australia
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Small Cell Lung Cancer (SCLC), Neuroendocrine Tumors
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Intrapatient dose escalation study of desipramine in subjects with small cell lung cancer (SCLC) and other high-grade neuroendocrine tumors.
- Trial name
- NCT01719861
- Testing
- Desipramine HCL
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Joel Neal
Glioblastoma
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM).
- Trial name
- NCT04225039
- Testing
- INCMGA00012, INCAGN01876, SRS
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pennsylvania
Glioma
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
The investigators have developed a phase I/II clinical trial to evaluate the effect of rhIL-7-hyFc on lymphocyte counts in patients with high grade glioma (HGG).
- Trial name
- NCT03687957
- Testing
- rhIL-7-hyFc, Temozolomide, Radiation therapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Glioblastoma Multiforme, Gliosarcoma
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I: The purpose of this research study is to determine the safety of the combination treatment of ZD6474 (Vandetanib) with the standard therapy for glioblastomas and gliosarcomas, temozolomide (Temodar) and radiation…
- Trial name
- Zactima (NCT00441142)
- Testing
- ZD6474, temozolomide, Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 119 people
- Sponsor
- Patrick Y. Wen, MD
Melanoma, Skin Cancer
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
In this study, we want to find out how likely it is for temozolomide to shrink melanoma tumors that have spread only to areas that could be removed by surgery.
- Conditions
- Melanoma, Skin Cancer, Cancer
- Trial name
- NCT00588341
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma, Head and Neck Cancer
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck…
- Conditions
- Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT02475213
- Testing
- Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2
- Where
- 20 sites in United States
- Volunteers
- 146 people
- Sponsor
- MacroGenics
Melanoma
Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
The purpose of this trial is to assess whether treatment with NY-ESO-1 ISCOMATRIX® vaccine improves outcomes for people with Malignant Melanoma which has been removed, but is at high risk of relapse.
- Trial name
- NCT00199901
- Testing
- NY-ESO-1 ISCOMATRIX®, ISCOMATRIX® adjuvant
- Where
- 15 sites in Australia, New Zealand and 1 more
- Volunteers
- 111 people
- Sponsor
- Ludwig Institute for Cancer Research
Neuroendocrine Tumors
Telotristat With Lutathera in Neuroendocrine Tumors
This trial will test the hypothesis that Telotristat treatment increases the antitumor efficacy of Lutetium Lu 177 Dotatate therapy in neuroendocrine tumors (NETs).
- Trial name
- NCT04543955
- Testing
- Telotristat (Low-Dose), Telotristat (High-Dose)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Lowell Anthony, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.